Abstract

A SYSTEMATIC REVIEW ON CARDIAC HYPERTROPHY

Arjesh Raj*

ABSTRACT

The occurrence of cardiac hypertrophy has risen over the last few decades. Myocardial hypertrophy, which is caused by an overgrowth of the ventricle wall, results in reduced pumping efficiency and blood pressure. The body responds by increasing the ventricle's pumping ability (ventricle thickening) to increase the ventricular wall capacity. On the other hand, high blood pressure and volume on the heart decreases the pumping capacity. It's called hypertrophied growth or hypertrophy when the tissue is overproduced and does not return to normal size after the operation is finished. Multiple factors are believed to contribute to cardiac hypertrophy.mitogen-activated protein kinase (IGF-I), PAR-4/nuclearPAR-3/calcalsinur are three inducers of protein kinase (PKNFA) is activated by calcium, calcium-calmodulin, and mammalian PI3K. An n A individual that is meant to be shot at with rapamycin (mTOR). Prevention technique for heart enlargement includes diuretics, ACE-inhibitors, antagonists, and blockers of the beta-AR (angiotensin) and CACNG receptor. This article examines the various signalling pathways and therapeutic methods necessary to combat them abnormal enlargement of the heart.

Keywords: Cardiac Hypertrophy, Disease, Etiology.